Koers Hemostemix Inc Toronto S.E.
Aandelen
CA4236941080
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 6,1 mln. 8,31 mln. 5,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -5 mln. -6,81 mln. -4,61 mln. | Nettowinst (verlies) 2023 | -2 mln. -2,73 mln. -1,84 mln. | EV/omzet 2022 | - |
Nettoschuld 2022 | 3,99 mln. 5,44 mln. 3,68 mln. | Nettoschuld 2023 | 4,17 mln. 5,68 mln. 3,84 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-2,41
x | K/w-verhouding 2023 |
-2,31
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 87,8% |
Recentste transcriptie over Hemostemix Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Thomas Smeenk
FOU | Founder | - | 01-01-06 |
Christina Wu
DFI | Director of Finance/CFO | - | 05-03-20 |
Peter Pavlin
COO | Chief Operating Officer | - | 19-05-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peter Lacey
CHM | Chairman | 67 | 11-03-20 |
Ronnie Hershmann
BRD | Director/Board Member | - | 09-02-20 |
Thomas Smeenk
FOU | Founder | - | 01-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,91% | 118 mld. | |
+11,60% | 106 mld. | |
-4,68% | 24,28 mld. | |
-0,82% | 21,96 mld. | |
-10,12% | 18,16 mld. | |
-42,12% | 16,37 mld. | |
-17,47% | 15,56 mld. | |
+2,77% | 13,63 mld. | |
+34,58% | 12,27 mld. |